GlassScriptPhysician profile
Stephen Paul Erickson
NPI 1477047975
$982.22
in general payments reported to CMS, 2019-2025
9 companies · $56.07 in 2025
The $56.07 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $77.03 · 2021: $106 · 2022: $303 · 2023: $115 · 2024: $136 · 2025: $56.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $245.47 | 2021-2023 | Libtayo |
| Abbvie INC. | $174.13 | 2022-2024 | |
| Allergan, INC. | $165.46 | 2019-2020 | |
| Incyte Corporation | $154.00 | 2022-2024 | Opzelura |
| Janssen Biotech, INC. | $118.90 | 2019-2024 | Tremfya |
| Kerecis Limited | $67.37 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Organogenesis INC. | $23.37 | 2025 | Affinity |
| Sun Pharmaceutical Industries INC. | $17.15 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.37 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.